Platform comparison—base quality & read length quality assessment.

<p>Per base quality scores and read length of all three platforms are shown for 454 (A, D), Illumina (B, E), and IonTorrent (C, F) using FASTQC algorithm.</p

Platform comparison—run details.

<p>Platform comparison—run details.</p

Platform comparison—amplicon-specific error rates.

<p>HTS platform-specific substitution (A) and Indel (B) error rates for amplicon libraries sequenced by 454 (black), Illumina (white), and IonTorrent (light grey) platform are displayed for single amplicons covering corresponding exons of the CREBBP gene.</p

Platform comparison—read distribution.

<p>Total number of reads (coverage) for each single barcoded amplicon library generated by 454 (A), Illumina (B), and IonTorrent (C) platform are shown in both forward (light grey) and reverse (dark grey) read orientation.</p

Platform comparison—error rates.

<p>Platform comparison—error rates.</p

Platform comparison—Base-specific error rates.

<p>Platform comparison—Base-specific error rates.</p

Universal two-step PCR approach.

<p>First-round PCR is performed by using gene-specific primers tailed with a universal linker sequence (light and dark green). The universal tailed amplicons can be used for second-round PCR, where deep sequencing platform-specific adapters can be introduced for either PGM (dark red), Illumina (blue), or 454 (orange). *To prepare PGM amplicon libraries containing trP1 and A adapter sequences on both ends of the library the second-round PCR has to be separated in two reactions with different primer combinations, respectively. All platform-specific amplicon libraries can be prepared with unique barcodes to sequence multiple samples.</p

Supplementary Figures from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

PDF file 79K, Supplementary Figure S1: Uptake of imatinib and OCT1 probe substrate TEA into OCT1-expressing cells and vector-transfected control cells Supplementary Figure S2: Cellular uptake of the OCT1 probe substrate TEA and imatinib into mOct1- or mOct2-expressing HEK293 cells Supplementary Figure S3: Cellular uptake of imatinib into the CML cell lines Meg-01, LAMA-84 and K562 as well as into OCT1-expressing HEK cells and vector-transfected control cells measured after an incubation period of 120 minutes Supplementary Figure S4: Cellular uptake of imatinib into HEK cells expressing variant V408 in comparison to HEK cells expressing reference sequence M408 and vector-transfected control cells measured after an incubation period of 10 minutes Supplementary Figure S5: Knockdown of OCT1 protein expression by the used shRNA</p

Supplementary Methods from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

PDF file 65K, Supplementary methods including chemicals, generation of a cell line expressing OCT1 variant p.V408, transport studies using oocytes and cell lines, LC-MS-MS analysis of imatinib, RNA isolation and quantification, shRNA knockdown, flow cytometry and confocal laser scanning microscopy</p

Supplementary Tables from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)

PDF file 64K, Supplementary Table S1. Overview of conflicting reports regarding the importance of OCT1 genetics, OCT1 expression, or cellular imatinib uptake for imatinib pharmacokinetics and response Supplementary Table S2. Multiple reaction monitoring transitions and MS parameters for determination of imatinib, N-desmethyl imatinib and their internal standards with LC-MS-MS Supplementary Table S3. Characteristics of SLC family members whose mRNA expression has been quantified by real-time PCR in the present study</p